Chan Chu
Bufo gargarizans Cantor
Also known as: Toad(English)
Ch'an Ch'u
Updated November 2, 2026 · Not yet clinically reviewed
Safety at a glance
5 recorded drug interactions, 4 major or contraindicated
No toxicity grade is recorded. Most herbs in the catalogue carry none.
Traditional Chinese Medicine
- Category
- clearing heat
- Temperature
- Cool
- Taste
- Pungent
- Channels
- Heart,Liver,Spleen,Lung
Functions
Eliminates abdominal masses, removes toxicity, induces diuresis, eliminates Dampness, kills parasites and alleviates pain; Opens the Orifices
Traditional uses
Chan Chu is the dried body (or the parotid-gland secretion, Chan Su) of the toad Bufo gargarizans, a pungent, warm, toxic substance of the Heart, Liver, Spleen and Lung channels. It is used to relieve toxicity, reduce swelling and stop pain for deep-rooted boils, carbuncles, abscesses, scrofula and toxic sores, and to open the orifices and disperse accumulation for abdominal masses, tympanites and infantile malnutrition (gan ji). Modern integrative oncology employs toad preparations (e.g., Hua Chan Su) as adjuncts in cancer care.
It is strongly toxic owing to bufadienolide cardiac glycosides. Internal use is minute (milligram-range), only in prepared form under expert supervision; overdose causes dangerous cardiac and gastrointestinal reactions. Contraindicated in pregnancy.
Formulas using this herb
1 of 1 formulas
- Mei Hua Dian She Dan · 3.00000g
Botanical
Chan Chu is the dried whole body of the toad, principally Bufo bufo gargarizans Cantor or Bufo melanostictus Schneider (Bufonidae), large nocturnal terrestrial amphibians widely distributed across East and Southeast Asia. Adult toads measure 7-12 cm in body length, with dry, warty, brown to grey dorsal skin and prominent parotoid glands behind the eyes that secrete a milky white venom containing bufadienolides (bufotalin, bufalin, cinobufagin) and biogenic amines. In classical TCM, the dried whole toad is considered acrid, cool, and toxic, used to resolve toxins, reduce swelling, dispel water, and treat carbuncles, scrofula, and edema. The white parotoid secretion, dried separately, constitutes the distinct drug Chan Su, used in small doses for shock, malignant boils, and certain cardiac conditions. Owing to the cardiotoxicity of bufadienolides, both Chan Chu and Chan Su are strictly dose-controlled in modern Chinese pharmacopoeial practice, and ingestion outside professional supervision can cause fatal arrhythmia.
- Pharmaceutical name
- Bufonis
- Parts used
- whole_animal
Constituents
Bufalin
Bufadienolide cardiac glycoside (cardioactive steroid)
One of the principal cardioactive steroids of the parotoid secretion. It inhibits the cardiac Na+/K+-ATPase in the same way as digoxin, which is the source of both the antitumour activity claimed for it and the fatal dysrhythmias seen in poisoning. It is potently cytotoxic in vitro (IC50 under 2.5 microM against A549, HCT-116, SK-Hep-1 and SKOV3 lines) and reached plasma concentrations of 0.81 to 3.38 ng/mL at the end of a two-hour infusion of the injectable preparation in the phase 1 trial.
Cinobufagin
Bufadienolide cardiac glycoside
A major bufadienolide of the secretion, named in the poisoning literature alongside bufalin and cinobufotalin as one of the cardioactive steroids responsible for the digoxin-like toxidrome, and one of the compounds credited with the antitumour effect of the injectable preparation.
Cinobufotalin
Bufadienolide cardiac glycoside
Present in dried toad venom from B. gargarizans and identified as one of the cardioactive steroids in both Chan Su and the aphrodisiac products made from the same material that killed four of six poisoned men in the New York case series.
Resibufogenin
Bufadienolide (bufogenin aglycone)
Described with cinobufagin and bufalin as one of the major cardiac glycosides carrying the antitumour activity of the injectable toad-venom preparation. Like the others, it is a Na+/K+-ATPase inhibitor and contributes to the cardiotoxicity.
Argentinogenin, gamabufalin and cinobufaginol
Bufadienolide
Three of the known bufadienolides recovered from the skins of B. gargarizans in a 2024 phytochemical study, all showing potent cytotoxicity with IC50 < 2.5 microM against lung, colon, liver and ovarian carcinoma lines. Potency in a cancer cell line and cardiac toxicity travel together in this compound class.
Desacetylcinobufagin and desacetylcinobufaginol
Bufadienolide
Known deacetylated bufadienolides from the toad skin, only moderately cytotoxic (IC50 < 50 microM) compared with the acetylated parents, indicating that the acetyl group carries much of the potency.
Bufalactamides A and B
Bufadienolide-derived lactam
Two previously undescribed bufadienolide derivatives isolated from B. gargarizans skin in 2024. Unlike the classical bufadienolides they were not cytotoxic (IC50 > 100 microM), which supported the structure-activity analysis in that paper.
Bufotalin and arenobufagin
Bufadienolide cardiac glycoside
Among the twelve bufadienolides routinely quantified in B. gargarizans venom by UPLC-MS/MS. The class as a whole acts by inhibiting the sodium pump, which is also how the secretion works as a chemical defence against predators, and it is a local irritant.
Drug interactions
Digoxin and other cardiac glycosides (digitoxin, ouabain)
Major · Additive Na+/K+-ATPase blockade producing vomiting, bradycardia, heart block and fatal ventricular dysrhythmias; deaths have occurred from the toad product alone · Evidence level: Established
The bufadienolides of B. gargarizans are cardioactive steroids that inhibit the cardiac sodium pump exactly as digoxin does, and the clinical course of poisoning is indistinguishable from digoxin toxicity. Six previously healthy men who ingested a product later shown to be identical to Chan Su developed vomiting and bradycardia and four died of dysrhythmias; a separate case of digitalis toxicity caused by toad venom is on record. Adding a cardiac glycoside to this drug adds two agents at the same receptor.
Clinical note: Do not combine. In a patient already on digoxin this is an absolute contraindication, and a patient presenting with a digitalis toxidrome after a Chinese medicine should be asked directly about toad-derived products. Digoxin-specific Fab fragments are the specific antidote and worked in the two survivors of the New York series and in a controlled mouse model.
Serum digoxin immunoassays (FPIA, MEIA, Digoxin II, Digoxin III)
Major · Both falsely high and falsely low digoxin results, depending on the assay, so the number the clinician acts on can be wrong in either direction · Evidence level: Established
The bufadienolides are structurally close enough to digoxin to cross-react with anti-digoxin antibodies. Aqueous Chan Su extract gave 2.76 ng/mL apparent digoxin by fluorescence polarization immunoassay, only 0.94 ng/mL by microparticle enzyme immunoassay and none by chemiluminescent assay; in patient serum pools it raised the FPIA result and lowered the MEIA result. With the newer Digoxin III assay, a pool containing 0.94 ng/mL true digoxin read 6.60 ng/mL after Chan Su was added while Digoxin II read 0.72 ng/mL, and the interference could not be removed by measuring free digoxin. Mice fed Chan Su showed apparent digoxin in serum, so the interference occurs in vivo. A monoclonal assay has separately been reported to fail to cross-react at all, which risks the opposite error of missing a genuine cardioactive-steroid poisoning.
Clinical note: A digoxin level in a patient exposed to toad venom cannot be interpreted at face value. Tell the laboratory what has been taken, find out which assay is in use, and treat the patient on the electrocardiogram, potassium and clinical picture, not the immunoassay number.
Potassium-depleting drugs (loop and thiazide diuretics, corticosteroids, amphotericin B)
Major · Hypokalaemia sensitises the myocardium to cardiac-glycoside dysrhythmias, lowering the dose at which the toad product becomes lethal · Evidence level: Probable
This is the standard potentiation described for cardioactive steroids as a class, and the bufadienolides act at the same target. It is an extrapolation from digitalis pharmacology to a drug that shares the mechanism, not an interaction that has been studied with the toad product itself.
Clinical note: Any patient on a potassium-wasting drug is a poor candidate for a toad-derived preparation. Check potassium if exposure has occurred.
Beta-blockers, verapamil and diltiazem
Moderate · Additive negative chronotropic and dromotropic effect, deepening bradycardia and atrioventricular block · Evidence level: Theoretical
Bradycardia is the presenting sign in toad-venom poisoning, and rate- and conduction-slowing cardiac drugs act on the same nodes. No study has combined them, so the reasoning is mechanistic.
Clinical note: Avoid the combination; if bradycardia develops in a patient on either drug class, consider toad-venom exposure as the precipitant rather than the background drug.
Toad-venom aphrodisiac and topical products sold as Love Stone, Stone, Rock Hard and similar
Major · Same cardioactive steroids as the medicinal drug, taken in an uncontrolled dose by people who do not know what they have taken; four deaths in one case series · Evidence level: Established
Chemical analysis of a purported topical aphrodisiac that poisoned six men showed it was identical to Chan Su, the Chinese medicinal preparation of dried B. gargarizans venom. Both contain bufalin, cinobufotalin, cinobufagin and other bufadienolides. This is the same drug reaching patients through a non-medical route, which is why it belongs in a practitioner's differential.
Clinical note: Ask about these products by their street names in any unexplained bradycardia or digitalis toxidrome. Warn patients that a toad-venom product bought outside a clinical setting has no dose control at all.
Dosage
| Form | Amount | Frequency | Notes |
|---|---|---|---|
| decoction | Dose not established here — see note | — | No Chinese Pharmacopoeia 2025 monograph found for this drug, so no pharmacopoeial dose is given here. Chan Chu is the whole dried toad (*Bufo gargarizans*), a different article from Chan Su (the gland secretion, 0.015–0.03 g) and from Chan Pi (the skin). It carries the same bufadienolide cardiac glycosides at lower and far more variable concentration, so a dose cannot be inferred from either sibling drug. Toxic; contraindicated in pregnancy. The previous value was generic filler generated from tcm_category and was cleared; it has not been replaced with an estimate. |
Evidence
Study design on record, not certainty of outcome.
- Other clinical trial
- 1
- Observational / case report
- 1
- In vitro / animal
- 4
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall‐cell lung cancer, or pancreatic cancer
Zhiqiang Meng; Peiying Yang; Yehua Shen; Wenying Bei; Ying Zhang; Yongqian Ge; Robert A. Newman; Lorenzo Cohen; Luming Liu; Bob Thornton; David Z. Chang; Zongxing Liao; Razelle Kurzrock · Cancer · 2009 · RCT
Other clinical trial · Verified
A phase 1 dose-escalation study of huachansu, the intravenous preparation of dried toad venom from B. gargarizans or B. melanostictus, in 15 patients (11 hepatocellular, 2 non-small-cell lung, 2 pancreatic). Doses ran from 10 to 90 mL/m2 over 14 days on, 7 days off. No dose-limiting toxicity was seen even at eight times the dose typically used in China, and 11 patients had no drug-related toxicity above grade 1. Six patients had stable disease (median 6.0 months) and one hepatocellular patient had 20% regression lasting 11 months at the lowest dose level. Plasma bufalin peaked at 0.81 to 3.38 ng/mL. This is a small uncontrolled phase 1 trial: it establishes tolerability of a standardised intravenous product, not efficacy, and says nothing about oral or self-administered toad preparations.
Treatment of Toad Venom Poisoning With Digoxin-Specific Fab Fragments
Jeffrey R. Brubacher; Padinjarekuttu R. Ravikumar; Theodore Bania; Michael B. Heller; Robert S. Hoffman · Chest · 1996 · cohort
Observational / case report · Verified
Six previously healthy men developed vomiting and bradycardia after ingesting a purported topical aphrodisiac. All had positive apparent digoxin levels; the first four died of cardiac dysrhythmias and the last two survived after digoxin-specific Fab fragments. Analysis showed the product was identical to Chan Su, the Chinese medication made from toad venom. The first reported use of digoxin Fab to treat toad venom poisoning.
Efficacy of digoxin specific Fab fragments (Digibind®) in the treatment of toad venom poisoning
J.R. Brubacher; D. Lachmanen; P.R. Ravikumar; R.S. Hoffman · Toxicon · 1999 · animal
In vitro / animal · Verified
Mice given an approximate LD90 dose of ethanolic Chan Su extract were pretreated with digoxin-specific Fab fragments or saline. All 30 control mice had seizures and died, against 11 seizures and 7 deaths among 15 treated mice (p = 0.00003 for mortality). The paper also states plainly that Chan Su and the Love Stone aphrodisiac are both made from dried venom of B. gargarizans and contain bufalin, cinobufotalin, cinobufagin and other bufadienolides, and that deaths have followed ingestion of these products.
Positive and Negative Interference of the Chinese Medicine Chan Su in Serum Digoxin Measurement
Amitava Dasgupta; David A. Biddle; Alice Wells; Pradip Datta · American Journal of Clinical Pathology · 2000 · in vitro
In vitro / animal · Not yet verified
Aqueous and organic extracts of Chan Su showed marked digoxin-like immunoreactivity: 20 microL of a 1 mg/mL aqueous extract added to 2 mL of drug-free serum read 2.76 ng/mL digoxin equivalent by FPIA, 0.94 ng/mL by MEIA and nothing by CLIA. In patient serum the extract raised the FPIA digoxin result and falsely lowered the MEIA result. Because Chan Su components are highly protein-bound while digoxin is only about 25% bound, measuring free digoxin removed the interference in both directions in these two assays.
Effect of Chinese Medicines Chan Su and Lu-Shen-Wan on Serum Digoxin Measurement by Digoxin III, a New Digoxin Immunoassay
Meredith A. Reyes; Jeffrey K. Actor; Semyon A. Risin; Amitava Dasgupta · Therapeutic Drug Monitoring · 2008 · in vitro
In vitro / animal · Not yet verified
Chan Su and the Chan Su-containing pill Lu-Shen-Wan cross-reacted significantly with the newer Digoxin III assay. A digoxin serum pool at 0.94 ng/mL supplemented with 5.0 micrograms/mL Chan Su extract read 6.60 ng/mL by Digoxin III and 6.99 ng/mL by FPIA, but a falsely low 0.72 ng/mL by Digoxin II. Unlike the older assays, the Digoxin III interference could not be eliminated by measuring free digoxin. Mice fed either medicine showed apparent digoxin in serum, confirming the interference occurs in vivo.
Structurally diverse bufadienolides from the skins of Bufo bufo gargarizans and their cytotoxicity
Lingjie Meng; Qian Cao; Xinyi Du; Huijing Lv; Chengjin Li; Xiaoke Zhang; Nian Jiang; Yi Xiao · Scientific Reports · 2024 · in vitro
In vitro / animal · Not yet verified
Two new bufadienolide derivatives, bufalactamides A and B, were isolated from the skins of B. gargarizans along with argentinogenin, desacetylcinobufagin, desacetylcinobufaginol, cinobufaginol, bufalin and gamabufalin. Argentinogenin, cinobufaginol, bufalin and gamabufalin were potently cytotoxic (IC50 < 2.5 microM) against A549, HCT-116, SK-Hep-1 and SKOV3; the desacetyl compounds were moderate (IC50 < 50 microM); and the two new lactams were inactive (IC50 > 100 microM).
References
- Jeffrey R. Brubacher; Robert S. Hoffman. Toad Venom Poisoning: Failure of a Monoclonal Digoxin Immunoassay to Cross-React with the Cardioactive Steroids. Journal of Toxicology: Clinical Toxicology. 1996 doi:10.3109/15563659609028014
- Tak Kwan; Augusto Dino Paiusco; Lewis Kohl. Digitalis Toxicity Caused by Toad Venom. Chest. 1992 doi:10.1378/chest.102.3.949